logo
logo
LifeStance Health Group, Inc.

LifeStance Health Group, Inc.

NASDAQ•LFST
CEO: Mr. Kenneth Alan Burdick
セクター: Healthcare
業種: Medical - Care Facilities
上場日: 2021-06-10
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
連絡先情報
4800 North Scottsdale Road, Suite 2300, Scottsdale, AZ, 85251, United States
602-767-2100
lifestance.com
時価総額
$2.70B
PER (TTM)
-295.0
33.4
配当利回り
--
52週高値
$8.30
52週安値
$3.74
52週レンジ
70%
順位63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 1.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$363.81M+16.34%
直近4四半期の推移

EPS

$0.00-117.83%
直近4四半期の推移

フリーCF

$17.00M-3.82%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Growth Total revenue reached $1.042B USD for nine months, up 13% from $925.5M USD last year.
Operating Income Turnaround Three month operating income $7.4M USD, massive improvement from $47K USD prior period comparison.
Net Loss Significantly Narrows Nine month net loss reduced to $2.0M USD versus $50.3M USD loss reported in 2024.
Operating Cash Flow Doubles Cash provided by operations $88.6M USD for nine months, nearly doubling prior year's $44.9M USD.

リスク要因

Internal Control Material Weakness Material weaknesses persist in internal control over financial reporting, impacting IT and accounting procedures.
Payor Rate Reduction Risk Business harmed if third-party payor reimbursement rates are reduced or care delivery is restrained by payors.
Reliance on Practice Relationships Business harmed if relationships with supported practices, which are not owned, are disrupted or face legal challenges.

見通し

Expanding Clinician Base Opportunity exists to grow employed clinician base from 7,996 as strategic recruiting efforts continue expansion plans.
Organic Center Growth Focus New center strategy central to organic growth, building capacity and increasing density in existing and new markets.
Drive Center Margin Growth Seek consistent returns by growing revenue and leveraging fixed costs; realize synergies from recent acquisitions.

同業比較

売上高 (TTM)

Ardent Health Partners, Inc.ARDT
$6.33B
+10.9%
Select Medical Holdings CorporationSEM
$3.93B
-35.0%
Acadia Healthcare Company, Inc.ACHC
$3.27B
+4.6%

粗利益率 (最新四半期)

Acadia Healthcare Company, Inc.ACHC
96.4%
+0.1pp
LeMaitre Vascular, Inc.LMAT
75.3%
+7.5pp
Artivion, Inc.AORT
65.6%
+1.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
BKD$3.87B-14.4-229.8%0.0%
LFST$2.70B-295.0-0.6%22.0%
NHC$2.52B24.910.0%8.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.8%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年2月26日
|
EPS:$0.05
|
売上高:$378.51M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $363.81M+16.3%
    |
    EPS: $0.00-117.8%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $345.31M+10.6%
    |
    EPS: $-0.01-84.0%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $332.97M+10.8%
    |
    EPS: $0.00-103.2%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $1.25B+18.5%
    |
    EPS: $-0.15+70.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $312.72M+19.0%
    |
    EPS: $-0.02-90.8%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $312.33M+20.3%
    |
    EPS: $-0.06-52.8%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月9日|
    売上高: $300.44M+18.9%
    |
    EPS: $-0.06-40.9%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月28日|
    売上高: $1.06B+22.8%
    |
    EPS: $-0.51+16.4%
    予想を下回る